SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).

Autor: Segura PP; Medical Oncology Department, Hospital Clínico San Carlos, IdISCC, Madrid, Spain., Quintela NV; Medical Oncology Department, Catalan Institute of Oncology, Barcelona, Spain.; Preclinical and Experimental Research in Thoracic Tumors (PReTT) Group, Oncobell Program, IDIBELL, L'Hospitalet, Barcelona, Spain., García MM; Medical Oncology Department, Hospital del Mar, Barcelona, Spain.; Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain., Del Barco Berrón S; Medical Oncology Department, Unidad Cáncer de Mama y Tumores Cerebrales, Instituto Catalán de Oncologia, Hospital Universitario Doctor Josep Trueta, Girona, Spain., Sarrió RG; Medical Oncology Department. Hospital, Univeristari i Politècnic La Fe, Valencia, Spain., Gómez JG; Medical Oncology Department, Complejo Hospitalario Universitario de Orense, Orense, Spain., Castaño AG; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Martín LMN; Medical Oncology Department, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain., Rubio OG; Medical Oncology Department, Hospital de Sant Pau i La Santa Creu, Barcelona, Spain., Losada EP; Medical Oncology Department, Hospital Clinic and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain. epineda@clinic.cat.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2023 Sep; Vol. 25 (9), pp. 2634-2646. Date of Electronic Publication: 2023 Aug 04.
DOI: 10.1007/s12094-023-03245-y
Abstrakt: High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: